Taysha Gene Therapies (TSHA) Financials

$6.81 +0.14 (+2.10%)

Closing price 05/8/2026 04:00 PM Eastern

Extended Trading

$6.84 +0.03 (+0.37%)

As of 05/8/2026 06:49 PM Eastern

Annual Income Statements for Taysha Gene Therapies

This table shows Taysha Gene Therapies' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-60	-175	-166	-112	-89	-109
Consolidated Net Income / (Loss)	-60	-175	-166	-112	-89	-109
Net Income / (Loss) Continuing Operations	-60	-175	-166	-112	-89	-109
Total Pre-Tax Income	-60	-175	-166	-112	-89	-109
Total Operating Income	-43	-173	-162	-72	-91	-110
Total Gross Profit	0.00	0.00	2.50	15	8.33	9.77
Total Revenue	0.00	0.00	2.50	15	8.33	9.77
Operating Revenue	-	0.00	2.50	15	8.33	9.77
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	43	173	165	88	100	120
Selling, General & Admin Expense	11	41	37	30	29	34
Research & Development Expense	32	132	91	57	66	86
Impairment Charge	-	0.00	36	1.07	4.84	0.00
Total Other Income / (Expense), net	-17	-1.26	-3.57	-39	2.16	1.50
Interest Expense	0.03	1.43	3.80	6.40	0.10	0.06
Interest & Investment Income	0.05	0.17	0.25	3.57	6.94	9.22
Other Income / (Expense), net	-17	0.00	-0.02	-36	-4.68	-7.66
Basic Earnings per Share	($3.40)	($4.64)	($3.78)	($0.96)	($0.36)	($0.34)
Weighted Average Basic Shares Outstanding	17.67M	37.65M	43.95M	116.12M	250.13M	319.71M
Diluted Earnings per Share	($3.40)	($4.64)	($3.78)	($0.96)	($0.36)	($0.34)
Weighted Average Diluted Shares Outstanding	17.67M	37.65M	43.95M	116.12M	250.13M	319.71M
Weighted Average Basic & Diluted Shares Outstanding	17.67M	37.65M	63.47M	187.02M	205.00M	287.27M

This table shows Taysha Gene Therapies' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-117	48	-24	-21	-26	-19	-22	-27	-33	-28	-42
Consolidated Net Income / (Loss)	-117	48	-24	-21	-26	-19	-22	-27	-33	-28	-42
Net Income / (Loss) Continuing Operations	-117	48	-24	-21	-26	-19	-22	-27	-33	-28	-42
Total Pre-Tax Income	-117	48	-24	-21	-26	-19	-22	-27	-33	-28	-42
Total Operating Income	-16	-16	-24	-21	-26	-20	-21	-27	-34	-28	-43
Total Gross Profit	4.75	3.60	3.41	1.11	1.79	2.02	2.30	1.99	0.00	5.49	0.00
Total Revenue	4.75	3.60	3.41	1.11	1.79	2.02	2.30	1.99	0.00	5.49	0.00
Operating Revenue	4.75	3.60	3.41	1.11	1.79	2.02	2.30	1.99	0.00	5.49	0.00
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	21	20	28	22	28	22	24	29	34	34	43
Selling, General & Admin Expense	8.59	6.72	7.08	7.34	7.90	6.63	8.16	8.60	8.28	8.83	9.68
Research & Development Expense	12	13	21	15	15	15	16	20	26	25	34
Impairment Charge	0.62	-	0.00	0.00	4.84	-	0.00	0.00	0.00	-	0.00
Total Other Income / (Expense), net	-101	64	0.27	0.37	0.37	1.15	-0.11	-0.13	1.29	0.45	1.08
Interest Expense	1.47	2.11	0.03	0.03	0.02	0.02	0.02	0.02	0.02	0.01	0.01
Interest & Investment Income	1.11	1.92	1.69	1.44	2.11	1.70	1.33	1.86	3.17	2.87	2.59
Other Income / (Expense), net	-100	64	-1.40	-1.04	-1.71	-0.53	-1.42	-1.97	-1.86	-2.41	-1.50
Basic Earnings per Share	($0.93)	$0.63	($0.10)	($0.09)	($0.10)	($0.07)	($0.08)	($0.09)	($0.09)	($0.08)	($0.12)
Weighted Average Basic Shares Outstanding	125.70M	116.12M	231.25M	232.82M	267.82M	250.13M	269.31M	297.99M	353.31M	319.71M	366.63M
Diluted Earnings per Share	($0.93)	$0.63	($0.10)	($0.09)	($0.10)	($0.07)	($0.08)	($0.09)	($0.09)	($0.08)	($0.12)
Weighted Average Diluted Shares Outstanding	125.70M	116.12M	231.25M	232.82M	267.82M	250.13M	269.31M	297.99M	353.31M	319.71M	366.63M
Weighted Average Basic & Diluted Shares Outstanding	186.96M	187.02M	187.02M	204.94M	204.94M	205.00M	214.66M	272.79M	273.92M	287.27M	287.36M

This table details how cash moves in and out of Taysha Gene Therapies' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	251	-100	-61	56	-4.90	181
Net Cash From Operating Activities	-31	-117	-88	-73	-81	-93
Net Cash From Continuing Operating Activities	-31	-117	-88	-73	-81	-93
Net Income / (Loss) Continuing Operations	-60	-175	-166	-112	-89	-109
Consolidated Net Income / (Loss)	-60	-175	-166	-112	-89	-109
Depreciation Expense	0.01	0.49	1.17	1.37	1.25	1.15
Non-Cash Adjustments To Reconcile Net Income	29	28	58	55	19	20
Changes in Operating Assets and Liabilities, net	-0.11	29	19	-18	-12	-5.37
Net Cash From Investing Activities	-9.08	-22	-25	-7.35	-0.36	-0.60
Net Cash From Continuing Investing Activities	-9.08	-22	-25	-7.35	-0.36	-0.60
Purchase of Property, Plant & Equipment	-0.08	-15	-21	-3.87	-0.37	-0.74
Other Investing Activities, net	-	0.00	-0.06	0.02	0.01	0.13
Net Cash From Financing Activities	291	39	52	136	77	275
Net Cash From Continuing Financing Activities	291	39	52	136	77	275
Repayment of Debt	-1.67	-0.51	-1.04	-44	-0.19	-41
Issuance of Debt	1.67	40	-	40	0.00	50
Issuance of Common Equity	166	0.00	53	0.57	77	264
Other Financing Activities, net	-	-0.36	-	140	0.00	1.22
Cash Interest Paid	0.03	0.64	2.78	4.95	5.28	5.40

This table details how cash moves in and out of Taysha Gene Therapies' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	119	-20	-20	49	-15	-19	-22	196	-15	23	-43
Net Cash From Operating Activities	-18	-16	-20	-22	-22	-18	-22	-20	-24	-27	-41
Net Cash From Continuing Operating Activities	-18	-16	-20	-22	-22	-18	-22	-20	-24	-27	-41
Net Income / (Loss) Continuing Operations	-117	48	-24	-21	-26	-19	-22	-27	-33	-28	-42
Consolidated Net Income / (Loss)	-117	48	-24	-21	-26	-19	-22	-27	-33	-28	-42
Depreciation Expense	0.33	0.37	0.33	0.32	0.29	0.30	0.28	0.28	0.29	0.30	0.30
Non-Cash Adjustments To Reconcile Net Income	106	-59	3.64	3.38	9.50	2.77	3.78	4.20	4.25	7.90	5.89
Changes in Operating Assets and Liabilities, net	-7.37	-4.85	0.30	-4.28	-5.88	-2.60	-4.56	2.23	4.03	-7.07	-4.65
Net Cash From Investing Activities	-3.49	-0.01	-0.14	-0.20	-0.04	0.01	-0.37	0.06	-0.05	-0.25	-3.02
Net Cash From Continuing Investing Activities	-3.49	-0.01	-0.14	-0.20	-0.04	0.01	-0.37	0.06	-0.05	-0.25	-3.02
Purchase of Property, Plant & Equipment	-	-0.02	0.00	-0.34	-0.04	0.00	-0.38	-0.38	-0.11	-0.25	-0.02
Acquisitions	-3.50	-	-0.14	0.14	-	-	0.00	0.38	-	-	-3.00
Other Investing Activities, net	0.01	0.01	0.00	-	-	0.01	0.01	0.06	0.06	0.00	0.00
Net Cash From Financing Activities	141	-4.25	-0.02	70	6.60	-0.36	-0.05	216	8.80	50	0.71
Net Cash From Continuing Financing Activities	141	-4.25	-0.02	70	6.60	-0.36	-0.05	216	8.80	50	0.71
Repayment of Debt	-0.10	-43	-0.05	-0.01	-0.17	0.00	-0.08	0.12	-0.29	-41	0.02
Issuance of Common Equity	141	-141	0.03	70	6.72	-0.36	0.08	216	-0.37	49	0.18
Other Financing Activities, net	-0.39	140	0.00	-	0.04	-	-0.05	-	-40	42	0.52
Cash Interest Paid	1.27	1.29	1.33	1.33	1.33	1.30	1.29	1.29	1.36	1.45	1.45

This table presents Taysha Gene Therapies' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	0.02	259	214	126	173	160	343
Total Current Assets	0.02	258	160	96	150	142	325
Cash & Equivalents	0.00	251	149	88	144	139	320
Restricted Cash	-	-	-	0.00	0.45	0.45	0.45
Prepaid Expenses	0.00	6.63	10	8.54	3.48	2.65	4.43
Other Current Assets	0.02	-	-	0.00	2.00	0.00	0.00
Plant, Property, & Equipment, net	0.00	0.29	51	15	11	7.49	6.74
Total Noncurrent Assets	0.00	0.72	3.74	15	12	11	12
Other Noncurrent Operating Assets	0.00	0.72	3.74	15	12	11	12
Total Liabilities & Shareholders' Equity	0.02	259	214	126	173	160	343
Total Liabilities	0.15	7.58	119	125	98	89	96
Total Current Liabilities	0.15	7.13	52	63	37	26	27
Accounts Payable	0.00	1.99	22	11	6.37	3.59	6.28
Accrued Expenses	0.15	5.14	30	18	12	13	20
Current Deferred Revenue	-	-	0.00	34	18	9.77	0.00
Total Noncurrent Liabilities	0.00	0.45	67	63	61	63	70
Long-Term Debt	-	0.00	37	38	41	44	50
Other Noncurrent Operating Liabilities	0.00	0.45	30	25	21	19	20
Commitments & Contingencies	0.00	-	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-0.14	251	95	0.95	75	72	247
Total Preferred & Common Equity	-0.14	251	95	0.95	75	72	247
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-0.14	251	95	0.95	75	72	247
Common Stock	0.98	312	331	402	588	678	958
Retained Earnings	-1.12	-61	-236	-401	-513	-602	-711
Accumulated Other Comprehensive Income / (Loss)	-	-	-	0.00	0.00	-4.03	-0.19

This table presents Taysha Gene Therapies' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	82	196	153	200	180	138	333	317	300
Total Current Assets	54	172	131	178	162	121	316	300	282
Cash & Equivalents	45	164	124	173	158	117	313	297	277
Restricted Cash	-	-	0.45	0.45	0.45	0.45	0.45	0.45	0.45
Prepaid Expenses	9.03	5.53	4.17	3.28	3.42	3.67	3.05	2.16	5.23
Other Current Assets	-	2.00	2.00	2.00	0.00	0.00	0.00	0.00	0.00
Plant, Property, & Equipment, net	14	11	11	11	7.61	7.24	6.96	6.81	6.45
Total Noncurrent Assets	13	13	12	11	11	10	10	9.80	12
Other Noncurrent Operating Assets	13	13	12	11	11	10	10	9.80	12
Total Liabilities & Shareholders' Equity	82	196	153	200	180	138	333	317	300
Total Liabilities	119	245	99	92	91	83	85	98	88
Total Current Liabilities	51	180	39	34	29	23	25	29	20
Accounts Payable	11	7.52	10	8.72	4.93	4.33	7.71	5.44	4.56
Accrued Expenses	20	14	14	12	13	11	12	18	16
Current Deferred Revenue	20	19	15	14	12	7.47	5.49	5.49	0.00
Total Noncurrent Liabilities	68	64	61	57	62	61	59	69	68
Long-Term Debt	38	39	41	38	43	42	41	51	49
Other Noncurrent Operating Liabilities	23	23	20	20	19	18	18	18	19
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-37	-49	54	109	89	55	249	219	212
Total Preferred & Common Equity	-37	-49	54	109	89	55	249	219	212
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-37	-49	54	109	89	55	249	219	212
Common Stock	407	512	591	664	675	681	900	904	965
Retained Earnings	-444	-561	-537	-558	-584	-624	-651	-683	-754
Accumulated Other Comprehensive Income / (Loss)	-	-	-0.25	2.41	-2.33	-2.29	-0.70	-1.14	0.99

This table displays calculated financial ratios and metrics derived from Taysha Gene Therapies' official financial filings.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	37,761,435.00	38,473,945.00	62,442,281.00	186,960,193.00	-	273,919,373.00
DEI Adjusted Shares Outstanding	37,761,435.00	38,473,945.00	62,442,281.00	186,960,193.00	-	273,919,373.00
DEI Earnings Per Adjusted Shares Outstanding	-1.59	-4.54	-2.66	-0.60	-	-0.40
Growth Metrics	-	-	-	-	-	-
Profitability Metrics	-	-	-	-	-	-
Net Operating Profit after Tax (NOPAT)	-30	-121	-114	-51	-64	-77
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-43.92%	-55.45%	-26.04%
Earnings before Interest and Taxes (EBIT)	-60	-173	-162	-109	-96	-118
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-60	-173	-161	-107	-95	-117
Valuation Ratios	-	-	-	-	-	-
Leverage & Solvency	-	-	-	-	-	-
Liquidity Ratios	-	-	-	-	-	-
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-105	-81	-71	-69	-78
Efficiency Ratios	-	-	-	-	-	-
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	0.05	-17	-49	-29	-24	-23
Increase / (Decrease) in Invested Capital	0.00	-17	-32	20	4.93	0.85
Book Value per Share	$6.66	$2.48	$0.02	$0.40	$0.35	$0.90
Tangible Book Value per Share	$6.66	$2.48	$0.02	$0.40	$0.35	$0.90
Total Capital	251	133	39	115	115	297
Total Debt	0.00	37	38	41	44	50
Total Long-Term Debt	0.00	37	38	41	44	50
Net Debt	-251	-112	-50	-104	-96	-270
Capital Expenditures (CapEx)	0.08	15	21	3.87	0.37	0.74
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-0.50	-41	-54	-31	-24	-22
Debt-free Net Working Capital (DFNWC)	251	108	34	113	116	298
Net Working Capital (NWC)	251	108	34	113	116	298
Net Nonoperating Expense (NNE)	30	53	52	61	25	32
Net Nonoperating Obligations (NNO)	-251	-112	-50	-104	-96	-270
Total Depreciation and Amortization (D&A)	0.01	0.49	1.17	1.37	1.25	1.15
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($3.40)	($4.64)	($3.78)	($0.96)	($0.36)	($0.34)
Adjusted Weighted Average Basic Shares Outstanding	37.76M	38.47M	43.95M	116.12M	250.13M	319.71M
Adjusted Diluted Earnings per Share	($3.40)	($4.64)	($3.78)	($0.96)	($0.36)	($0.34)
Adjusted Weighted Average Diluted Shares Outstanding	37.76M	38.47M	43.95M	116.12M	250.13M	319.71M
Adjusted Basic & Diluted Earnings per Share	($3.40)	($4.64)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	17.67M	37.65M	63.47M	187.02M	205.00M	287.27M
Normalized Net Operating Profit after Tax (NOPAT)	-30	-121	-88	-50	-61	-77
Debt Service Ratios	-	-	-	-	-	-
Payout Ratios	-	-	-	-	-	-

This table displays calculated financial ratios and metrics derived from Taysha Gene Therapies' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	64,465,037.00	186,960,193.00	187,018,275.00	187,018,275.00	204,943,306.00	-	205,001,632.00	214,661,715.00	272,794,885.00	273,919,373.00	287,269,885.00
DEI Adjusted Shares Outstanding	64,465,037.00	186,960,193.00	187,018,275.00	187,018,275.00	204,943,306.00	-	205,001,632.00	214,661,715.00	272,794,885.00	273,919,373.00	287,269,885.00
DEI Earnings Per Adjusted Shares Outstanding	-1.82	0.26	-0.13	-0.11	-0.12	-	-0.11	-0.13	-0.12	-0.10	-0.15
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	44.04%	-27.52%	-53.57%	-62.33%	-43.90%	-32.51%	78.60%	-100.00%	-	-100.00%
EBITDA Growth	-362.23%	190.09%	-56.44%	4.42%	76.53%	-141.74%	11.21%	-29.19%	-30.34%	-	-98.16%
EBIT Growth	-358.50%	188.81%	-55.28%	4.45%	76.35%	-142.69%	11.23%	-28.57%	-29.99%	-	-97.00%
NOPAT Growth	36.17%	56.99%	-46.93%	8.92%	-59.37%	14.12%	11.96%	-25.61%	-31.38%	-	-103.01%
Net Income Growth	-341.39%	186.68%	-36.54%	14.92%	78.20%	-139.35%	10.52%	-28.45%	-28.24%	-	-96.99%
EPS Growth	-43.08%	165.63%	64.29%	76.32%	89.25%	-111.11%	20.00%	0.00%	10.00%	-	-50.00%
Operating Cash Flow Growth	37.70%	-209.55%	1.92%	-14.58%	-20.42%	-13.59%	-11.22%	6.15%	-11.80%	-	-85.64%
Free Cash Flow Firm Growth	436.02%	-579.11%	-239.87%	-206.41%	-193.56%	47.94%	6.04%	32.48%	86.65%	-	-32.58%
Invested Capital Growth	-1,298.14%	40.89%	25.23%	39.58%	84.92%	17.02%	35.05%	11.54%	-6.00%	-	17.46%
Revenue Q/Q Growth	98.16%	-24.06%	-5.36%	-67.40%	60.79%	13.09%	13.85%	-13.73%	-100.00%	-	-100.00%
EBITDA Q/Q Growth	-405.23%	141.49%	-152.59%	13.31%	-24.04%	26.19%	-11.88%	-26.13%	-25.15%	-	-46.96%
EBIT Q/Q Growth	-399.23%	141.06%	-153.67%	13.15%	-23.57%	25.88%	-11.60%	-25.78%	-24.94%	-	-46.49%
NOPAT Q/Q Growth	30.51%	-42.82%	-4.83%	12.46%	-21.59%	23.04%	-7.47%	-24.89%	-27.18%	-	-53.66%
Net Income Q/Q Growth	-376.00%	140.77%	-150.40%	13.02%	-21.96%	26.40%	-14.61%	-24.86%	-21.77%	-	-52.27%
EPS Q/Q Growth	-144.74%	167.74%	-115.87%	10.00%	-11.11%	30.00%	-14.29%	-12.50%	0.00%	-	-50.00%
Operating Cash Flow Q/Q Growth	4.36%	10.21%	-22.84%	-8.62%	-0.52%	15.30%	-20.28%	8.35%	-19.74%	-	-52.98%
Free Cash Flow Firm Q/Q Growth	487.29%	-120.37%	25.07%	-18.72%	-416.39%	88.67%	-35.25%	14.68%	-2.06%	-	-63.88%
Invested Capital Q/Q Growth	-298.80%	83.45%	-3.88%	11.90%	0.45%	8.92%	18.69%	-19.98%	-19.29%	-	30.43%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%	-	0.00%
EBITDA Margin	-2,452.47%	1,340.09%	-744.65%	-1,980.13%	-1,527.57%	-996.98%	-979.71%	-1,432.38%	0.00%	-	0.00%
Operating Margin	-342.39%	-450.78%	-713.28%	-1,915.38%	-1,448.43%	-985.76%	-930.54%	-1,347.08%	0.00%	-	0.00%
EBIT Margin	-2,459.44%	1,329.94%	-754.18%	-2,009.08%	-1,544.02%	-1,012.02%	-992.01%	-1,446.32%	0.00%	-	0.00%
Profit (Net Income) Margin	-2,467.07%	1,324.67%	-705.39%	-1,882.01%	-1,427.52%	-929.03%	-935.23%	-1,353.58%	0.00%	-	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	-	100.00%
Interest Burden Percent	100.31%	99.60%	93.53%	93.68%	92.45%	91.80%	94.28%	93.59%	91.21%	-	94.27%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Return on Equity (ROE)	1,128.70%	-294.04%	-606.69%	-318.69%	-114.77%	-121.94%	-159.34%	-51.86%	-64.93%	-	-97.28%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Operating Return on Assets (OROA)	-229.73%	137.45%	-83.87%	-183.47%	-81.43%	-50.64%	-49.19%	-43.89%	0.00%	-	0.00%
Return on Assets (ROA)	-230.44%	136.90%	-78.44%	-171.86%	-75.29%	-46.48%	-46.38%	-41.07%	0.00%	-	0.00%
Return on Common Equity (ROCE)	1,128.70%	-294.04%	-606.69%	-318.69%	-114.77%	-121.94%	-159.34%	-51.86%	-64.93%	-	-97.28%
Return on Equity Simple (ROE_SIMPLE)	436.50%	0.00%	-219.14%	0.00%	0.00%	0.00%	-157.59%	0.00%	0.00%	-	0.00%
Net Operating Profit after Tax (NOPAT)	-11	-16	-17	-15	-18	-14	-15	-19	-24	-20	-30
NOPAT Margin	-239.68%	-450.78%	-499.30%	-1,340.76%	-1,013.90%	-690.03%	-651.38%	-942.96%	0.00%	-	0.00%
Net Nonoperating Expense Percent (NNEP)	-172.93%	83.21%	-12.88%	-8.47%	-6.14%	-4.85%	-8.24%	-4.00%	-4.92%	-	-7.91%
Return On Investment Capital (ROIC_SIMPLE)	-	-14.07%	-18.05%	-10.16%	-13.76%	-12.08%	-15.38%	-6.46%	-8.83%	-6.67%	-11.67%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
SG&A Expenses to Revenue	180.97%	186.43%	207.68%	659.89%	441.95%	327.84%	354.39%	432.93%	0.00%	-	0.00%
R&D to Revenue	248.44%	351.89%	605.60%	1,355.49%	835.91%	757.91%	676.15%	1,014.15%	0.00%	-	0.00%
Operating Expenses to Revenue	442.39%	550.78%	813.28%	2,015.38%	1,548.43%	1,085.76%	1,030.54%	1,447.08%	0.00%	-	0.00%
Earnings before Interest and Taxes (EBIT)	-117	48	-26	-22	-28	-20	-23	-29	-36	-31	-45
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-116	48	-25	-22	-27	-20	-23	-28	-36	-30	-45
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	4.42	9.97	3.85	4.64	4.96	5.18	1.99	4.07	-	6.06
Price to Tangible Book Value (P/TBV)	0.00	4.42	9.97	3.85	4.64	4.96	5.18	1.99	4.07	-	6.06
Price to Revenue (P/Rev)	14.20	21.42	37.92	32.54	41.55	42.55	39.45	61.23	141.37	-	171.88
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Enterprise Value to Revenue (EV/Rev)	5.43	14.69	31.99	22.03	29.93	31.08	29.12	27.63	102.23	-	141.35
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.69	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-0.78	0.54	0.75	0.35	0.48	0.61	0.77	0.17	0.23	-	0.23
Long-Term Debt to Equity	-0.78	0.54	0.75	0.35	0.48	0.61	0.77	0.17	0.23	-	0.23
Financial Leverage	3.22	-2.03	-2.81	-1.98	-6.07	-1.36	-1.46	-1.14	-1.18	-	-1.13
Leverage Ratio	-8.09	3.94	6.54	3.93	9.47	2.27	2.68	1.49	1.61	-	1.64
Compound Leverage Factor	-8.11	3.92	6.12	3.68	8.76	2.09	2.52	1.40	1.47	-	1.55
Debt to Total Capital	-364.83%	35.09%	42.93%	25.79%	32.61%	38.06%	43.54%	14.17%	18.85%	-	18.77%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Long-Term Debt to Total Capital	-364.83%	35.09%	42.93%	25.79%	32.61%	38.06%	43.54%	14.17%	18.85%	-	18.77%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Common Equity to Total Capital	464.83%	64.91%	57.07%	74.21%	67.39%	61.94%	56.46%	85.83%	81.15%	-	81.23%
Debt to EBITDA	-0.18	-0.38	-0.35	-0.33	-1.63	-0.46	-0.46	-0.42	-0.48	-	-0.35
Net Debt to EBITDA	0.60	0.97	0.72	1.17	4.36	1.01	0.81	2.76	2.31	-	1.64
Long-Term Debt to EBITDA	-0.18	-0.38	-0.35	-0.33	-1.63	-0.46	-0.46	-0.42	-0.48	-	-0.35
Debt to NOPAT	-0.50	-0.80	-0.72	-0.69	-0.70	-0.69	-0.68	-0.62	-0.71	-	-0.53
Net Debt to NOPAT	1.63	2.05	1.49	2.48	1.87	1.49	1.20	4.14	3.45	-	2.46
Long-Term Debt to NOPAT	-0.50	-0.80	-0.72	-0.69	-0.70	-0.69	-0.68	-0.62	-0.71	-	-0.53
Altman Z-Score	-5.46	-0.34	-1.41	-0.59	-1.40	-2.37	-3.90	1.57	3.14	-	5.78
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.95	4.08	3.38	5.22	5.51	5.42	5.35	12.48	10.48	-	14.04
Quick Ratio	0.91	3.92	3.21	5.05	5.38	5.30	5.17	12.34	10.39	-	13.76
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	178	-36	-27	-32	-167	-19	-26	-22	-22	-21	-34
Operating Cash Flow to CapEx	0.00%	-94,805.88%	0.00%	-6,306.16%	-61,757.14%	0.00%	0.00%	-5,311.05%	-22,375.93%	-	-170,325.00%
Free Cash Flow to Firm to Interest Expense	121.05	-17.18	-937.07	-1,194.94	-6,941.82	-858.11	-1,343.83	-1,281.42	-1,482.25	-	-3,761.13
Operating Cash Flow to Interest Expense	-12.20	-7.63	-682.69	-796.44	-900.63	-832.18	-1,158.95	-1,187.18	-1,611.07	-	-4,542.00
Operating Cash Flow Less CapEx to Interest Expense	-12.20	-7.64	-682.69	-809.07	-902.08	-832.09	-1,158.95	-1,209.53	-1,618.27	-	-4,544.67
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.09	0.10	0.11	0.09	0.05	0.05	0.05	0.03	0.03	-	0.03
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Fixed Asset Turnover	0.38	1.20	1.12	1.04	1.06	0.91	0.81	0.93	0.88	-	1.09
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-175	-29	-30	-26	-26	-24	-20	-23	-28	-23	-16
Invested Capital Turnover	-0.18	-0.40	-0.40	-0.37	-0.10	-0.31	-0.29	-0.32	-0.23	-	-0.42
Increase / (Decrease) in Invested Capital	-189	20	10	17	148	4.93	11	3.06	-1.58	0.85	3.41
Enterprise Value (EV)	78	227	453	284	297	259	210	224	645	-	1,056
Market Capitalization	204	331	537	419	412	355	285	496	892	-	1,284
Book Value per Share	($0.76)	$0.40	$0.29	$0.58	$0.43	$0.35	$0.27	$1.16	$0.80	$0.90	$0.74
Tangible Book Value per Share	($0.76)	$0.40	$0.29	$0.58	$0.43	$0.35	$0.27	$1.16	$0.80	$0.90	$0.74
Total Capital	-11	115	94	147	132	115	98	290	270	297	261
Total Debt	39	41	41	38	43	44	42	41	51	50	49
Total Long-Term Debt	39	41	41	38	43	44	42	41	51	50	49
Net Debt	-126	-104	-84	-135	-115	-96	-75	-272	-247	-270	-228
Capital Expenditures (CapEx)	0.00	0.02	0.00	0.34	0.04	-0.00	0.00	0.38	0.11	0.25	0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-173	-31	-32	-29	-26	-24	-19	-22	-26	-22	-15
Debt-free Net Working Capital (DFNWC)	-8.64	113	92	144	132	116	98	291	271	298	262
Net Working Capital (NWC)	-8.64	113	92	144	132	116	98	291	271	298	262
Net Nonoperating Expense (NNE)	106	-64	7.03	6.02	7.40	4.83	6.53	8.15	8.92	8.04	12
Net Nonoperating Obligations (NNO)	-126	-104	-84	-135	-115	-96	-75	-272	-247	-270	-228
Total Depreciation and Amortization (D&A)	0.33	0.37	0.33	0.32	0.29	0.30	0.28	0.28	0.29	0.30	0.30
Debt-free, Cash-free Net Working Capital to Revenue	-1,205.12%	-202.43%	-229.37%	-224.49%	-261.39%	-283.00%	-261.50%	-275.31%	-419.54%	-	-199.08%
Debt-free Net Working Capital to Revenue	-60.24%	732.07%	649.62%	1,120.90%	1,333.54%	1,390.89%	1,358.68%	3,592.43%	4,299.84%	-	3,508.93%
Net Working Capital to Revenue	-60.24%	732.07%	649.62%	1,120.90%	1,333.54%	1,390.89%	1,358.68%	3,592.43%	4,299.84%	-	3,508.93%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.93)	$0.63	($0.10)	($0.09)	($0.10)	($0.07)	($0.08)	($0.09)	($0.09)	($0.08)	($0.12)
Adjusted Weighted Average Basic Shares Outstanding	125.70M	116.12M	231.25M	232.82M	267.82M	250.13M	269.31M	297.99M	353.31M	319.71M	366.63M
Adjusted Diluted Earnings per Share	($0.93)	$0.63	($0.10)	($0.09)	($0.10)	($0.07)	($0.08)	($0.09)	($0.09)	($0.08)	($0.12)
Adjusted Weighted Average Diluted Shares Outstanding	125.70M	116.12M	231.25M	232.82M	267.82M	250.13M	269.31M	297.99M	353.31M	319.71M	366.63M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	186.96M	187.02M	187.02M	204.94M	204.94M	205.00M	214.66M	272.79M	273.92M	287.27M	287.36M
Normalized Net Operating Profit after Tax (NOPAT)	-11	-11	-17	-15	-15	-14	-15	-19	-24	-20	-30
Normalized NOPAT Margin	-230.59%	-315.54%	-499.30%	-1,340.76%	-824.50%	-690.03%	-651.38%	-942.96%	0.00%	-	0.00%
Pre Tax Income Margin	-2,467.07%	1,324.67%	-705.39%	-1,882.01%	-1,427.52%	-929.03%	-935.23%	-1,353.58%	0.00%	-	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-79.35	22.71	-887.07	-827.44	-1,150.29	-930.14	-1,201.89	-1,689.65	-2,392.47	-	-4,998.56
NOPAT to Interest Expense	-7.73	-7.70	-587.28	-552.20	-755.36	-634.20	-789.19	-1,101.59	-1,587.79	-	-3,382.24
EBIT Less CapEx to Interest Expense	-79.35	22.70	-887.07	-840.07	-1,151.75	-930.05	-1,201.89	-1,712.00	-2,399.67	-	-5,001.22
NOPAT Less CapEx to Interest Expense	-7.73	-7.70	-587.28	-564.83	-756.82	-634.11	-789.19	-1,123.95	-1,594.99	-	-3,384.91
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%

Financials Breakdown Chart

Key Financial Trends

Here are the key takeaways from TSHA's recent quarterly statements, focusing on liquidity, funding, and profitability trends over the last several years. The data show a company still posting losses, but actively raising capital to fund operations and maintaining a sizable cash position.

In Q2 2025, TSHA issued common equity and raised about $216.2 million, with net cash from continuing financing activities around $216.3 million, supporting liquidity.
Cash and cash equivalents were about $312.8 million at 6/30/2025, up from early 2025 levels, reflecting the financing runway.
Total assets rose to about $333.3 million by 6/30/2025, a notable increase from roughly $138.4 million at the start of 2025, aided by new equity proceeds and asset growth.
Financing inflows were robust in 2025, with approximately $216.3 million in Q2 and about $49.6 million in Q4 2025, helping offset operating cash burn.
Q4 2025 revenue reached about $5.5 million, showing topline progress amid ongoing R&D investment.
Total Common Equity was about $219 million by Q3 2025 and remained around that level in Q4 2025, reflecting capital raise activity.
Net income declined to about -$27.9 million in Q4 2025 (Consolidated Net Income / Loss), continuing a negative earnings trend.
Net cash from continuing operating activities was negative in Q4 2025 at about -$26.7 million, indicating ongoing cash burn from core operations.
Retained earnings show a substantial cumulative deficit (e.g., -$683.4 million by Q3 2025), underscoring long-term funding needs to support development programs.

05/09/26 03:38 AM ETAI Generated. May Contain Errors.

Taysha Gene Therapies Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Taysha Gene Therapies' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Over the last 5 years, Taysha Gene Therapies' net income changed from -$60.01 million in 2020 to -$109.00 million in 2025, a change of 81.6%. Find out what analysts predict for Taysha Gene Therapies in the coming months.

Taysha Gene Therapies' total operating income in 2025 was -$110.50 million, based on the following breakdown:

Total Gross Profit: $9.77 million
Total Operating Expenses: $120.27 million

Over the last 5 years, Taysha Gene Therapies' total revenue changed from $0.00 in 2020 to $9.77 million in 2025, a change of 977,300,000.0%.

Taysha Gene Therapies' total liabilities were at $96.38 million at the end of 2025, a 8.5% increase from 2024, and a 64,154.7% increase since 2019.

In the past 6 years, Taysha Gene Therapies' cash and equivalents has ranged from $0.00 in 2019 to $319.77 million in 2025, and is currently $319.77 million as of their latest financial filing in 2025.

Over the last 5 years, Taysha Gene Therapies' book value per share changed from 6.66 in 2020 to 0.90 in 2025, a change of -86.5%.

Related Companies

Financial statements for NASDAQ:TSHA last updated on 5/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Taysha Gene Therapies (TSHA) Financials

Financials Breakdown Chart

Key Financial Trends

Taysha Gene Therapies Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Taysha Gene Therapies (TSHA) Financials

Annual Income Statements for Taysha Gene Therapies

Quarterly Income Statements for Taysha Gene Therapies

Annual Cash Flow Statements for Taysha Gene Therapies

Quarterly Cash Flow Statements for Taysha Gene Therapies

Annual Balance Sheets for Taysha Gene Therapies

Quarterly Balance Sheets for Taysha Gene Therapies

Annual Metrics And Ratios for Taysha Gene Therapies

Quarterly Metrics And Ratios for Taysha Gene Therapies

Financials Breakdown Chart

Key Financial Trends

Taysha Gene Therapies Financials - Frequently Asked Questions

When does Taysha Gene Therapies' fiscal year end?

How has Taysha Gene Therapies' net income changed over the last 5 years?

What is Taysha Gene Therapies' operating income?

How has Taysha Gene Therapies' revenue changed over the last 5 years?

How much debt does Taysha Gene Therapies have?

How much cash does Taysha Gene Therapies have?

How has Taysha Gene Therapies' book value per share changed over the last 5 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools